Honeywell announced the introduction of a new RNA reagent for use in developing advanced therapeutic medicines.
The product, the Burdick & Jackson rBMI activator, is designed to help laboratories reduce the use of costly amidites, critical ingredients used in the process of making RNA-based medicines, without reducing RNA yield from the process.
The patented formulation is also blended to help the activator remain stable in cold temperatures, which ensures that laboratories will have a product that can be reliably shipped, stored, and handled during the winter months.
The new rBMI activator is formulated to help labs develop therapeutic medicines in a more efficient and productive way. The activator maintains the high level of purity that the pharmaceutical industry has come to expect from Burdick & Jackson for more than five decades.”
Honeywell’s rBMI activator is an extension of the Burdick & Jackson BioSyn line of high-purity DNA and RNA reagents, which are key components in the development of new therapeutic medicines to treat cancer, diabetes, and many other diseases.
The new reagent, consisting of a BMT-type activator, reduces the amount of amidites needed for RNA synthesis without sacrificing the yield of the synthesis, when compared with ETT-type activators. The activator is blended with NMI, a substance that helps to improve the solubility of the formulation. As with all BioSyn reagents, the rBMI activator has low water content for moisture-sensitive applications.
BioSyn DNA and RNA solvents and reagents are engineered to meet the high purity and consistency standards that the pharmaceutical industry requires. A wide range of packaging options, from glass bottles to bulk containers, are available to meet laboratory or production needs.
